Researchers from the Sino-American Cancer Foundation and Taipei Medical University have developed a novel nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1) for the possible treatment of acute myeloid leukemia (AML).
Liminatus Pharma Inc. has announced plans to conduct a phase I trial of IBA-101, a next-generation CD47-blockade antibody designed to work alongside PD-1/PD-L1 checkpoint inhibitors across a range of solid tumors.
Glioblastoma multiforme (GBM) is an aggressive and highly invasive intracranial tumor arising from the malignant transformation of brain and spinal cord cells. To date, surgery followed by adjuvant chemotherapy is the standard therapy for treating GBM, where temozolomide is the only first-line FDA-approved drug for GBM treatment. The aim of this study from Shenzhen University was to test the effect of a novel chloroethyl nitrosourea analog, HJ-03, in the treatment of GBM, which might overcome temozolomide resistance.
Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.
Asieris Pharmaceuticals Co. Ltd. has patented new prodrugs of fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.
Boomray Co. Ltd. has prepared and tested new peptide-drug conjugates comprising a radionuclide-labeled probe linked to a fibroblast activation protein α (FAP)-targeting peptide. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis and scars.
Sprint Bioscience AB has announced positive results from a preclinical proof-of-concept (POC) study performed within the company’s VRK1 program that showed that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected.
Mestag Therapeutics Ltd. has raised a $40 million round from existing investors as it completes final preparations for its lead program MST-0312 to enter clinical development in mid-2026. MST-0312 is a bispecific antibody aimed at the lymphotoxin-β receptor (LTBR), which is essential for the development of lymphoid tissues.
Eisai Co. Ltd. has patented immunoconjugates comprising monoclonal antibodies targeting 5’-nucleotidase (CD73) covalently linked to cytotoxic drug. They are reported to be useful for the treatment of cancer.
RSS
